A retrospective study on potential drug interactions: A single center experience

Background: In this study, it is aimed to explain the type and frequency of potential drug-drug interactions (pDDI) in patients a Medical oncology service. Methods: This study retrospective descriptive design. pDDIs were identified using the checker programme (Medscape®). Interactions were classifie...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Fatma Ceyda Korucu [verfasserIn] Ece Senyigit [verfasserIn] Osman Köstek [verfasserIn] Nazım Can Demircan [verfasserIn] Bulent Erdogan [verfasserIn] Sernaz Uzunoglu [verfasserIn] Irfan Cicin [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2018

Übergeordnetes Werk:	In: Journal of Oncological Sciences - Turkiye Klinikleri, 2017, 4(2018), 2, Seite 80-84
Übergeordnetes Werk:	volume:4 ; year:2018 ; number:2 ; pages:80-84

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.1016/j.jons.2018.06.001

Katalog-ID:	DOAJ006508707

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ006508707
003	DE-627
005	20230503143331.0
007	cr uuu---uuuuu
008	230225s2018 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1016/j.jons.2018.06.001 \|2 doi
035			\|a (DE-627)DOAJ006508707
035			\|a (DE-599)DOAJ5a820194e0fc47629a982aed4ba5ecb9
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC254-282
100	0		\|a Fatma Ceyda Korucu \|e verfasserin \|4 aut
245	1	2	\|a A retrospective study on potential drug interactions: A single center experience
264		1	\|c 2018
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Background: In this study, it is aimed to explain the type and frequency of potential drug-drug interactions (pDDI) in patients a Medical oncology service. Methods: This study retrospective descriptive design. pDDIs were identified using the checker programme (Medscape®). Interactions were classified according to their clinical relevance as minor, moderate and major as appropriate. Results: The prevalence of pDDIs was 71.3% and median age was 61 years-old (interquartile range 54–68) and female to male ratio was 116/211. The median number of drugs per patient was 8 (interquartile range 5–10). A total of 1102 pDDIs of 327 hospitalized cancer patients were identified. Of those, 16.7% were major and 61.8% moderate, respectively. Concomitant use of opioids was the most common interaction in our study. Conclusions: Drug interactions were common in hospitalized cancer patients. In order to prevent potential hazardous effect of pDDI, awareness of the physicians should be increased about this issue. Keywords: Cancer patients, Oncology, Polypharmacy, Drug interaction, Chemotherapy
653		0	\|a Neoplasms. Tumors. Oncology. Including cancer and carcinogens
700	0		\|a Ece Senyigit \|e verfasserin \|4 aut
700	0		\|a Osman Köstek \|e verfasserin \|4 aut
700	0		\|a Nazım Can Demircan \|e verfasserin \|4 aut
700	0		\|a Bulent Erdogan \|e verfasserin \|4 aut
700	0		\|a Sernaz Uzunoglu \|e verfasserin \|4 aut
700	0		\|a Irfan Cicin \|e verfasserin \|4 aut
773	0	8	\|i In \|t Journal of Oncological Sciences \|d Turkiye Klinikleri, 2017 \|g 4(2018), 2, Seite 80-84 \|w (DE-627)860839109 \|w (DE-600)2858461-2 \|x 24523364 \|7 nnns
773	1	8	\|g volume:4 \|g year:2018 \|g number:2 \|g pages:80-84
856	4	0	\|u https://doi.org/10.1016/j.jons.2018.06.001 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/5a820194e0fc47629a982aed4ba5ecb9 \|z kostenfrei
856	4	0	\|u http://www.sciencedirect.com/science/article/pii/S245233641830013X \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2452-3364 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 4 \|j 2018 \|e 2 \|h 80-84

Indexfelder

author_variant	f c k fck e s es o k ok n c d ncd b e be s u su i c ic
matchkey_str	article:24523364:2018----::rtopcietdoptnilrgneatossn
hierarchy_sort_str	2018
callnumber-subject-code	RC
publishDate	2018
allfields	10.1016/j.jons.2018.06.001 doi (DE-627)DOAJ006508707 (DE-599)DOAJ5a820194e0fc47629a982aed4ba5ecb9 DE-627 ger DE-627 rakwb eng RC254-282 Fatma Ceyda Korucu verfasserin aut A retrospective study on potential drug interactions: A single center experience 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: In this study, it is aimed to explain the type and frequency of potential drug-drug interactions (pDDI) in patients a Medical oncology service. Methods: This study retrospective descriptive design. pDDIs were identified using the checker programme (Medscape®). Interactions were classified according to their clinical relevance as minor, moderate and major as appropriate. Results: The prevalence of pDDIs was 71.3% and median age was 61 years-old (interquartile range 54–68) and female to male ratio was 116/211. The median number of drugs per patient was 8 (interquartile range 5–10). A total of 1102 pDDIs of 327 hospitalized cancer patients were identified. Of those, 16.7% were major and 61.8% moderate, respectively. Concomitant use of opioids was the most common interaction in our study. Conclusions: Drug interactions were common in hospitalized cancer patients. In order to prevent potential hazardous effect of pDDI, awareness of the physicians should be increased about this issue. Keywords: Cancer patients, Oncology, Polypharmacy, Drug interaction, Chemotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens Ece Senyigit verfasserin aut Osman Köstek verfasserin aut Nazım Can Demircan verfasserin aut Bulent Erdogan verfasserin aut Sernaz Uzunoglu verfasserin aut Irfan Cicin verfasserin aut In Journal of Oncological Sciences Turkiye Klinikleri, 2017 4(2018), 2, Seite 80-84 (DE-627)860839109 (DE-600)2858461-2 24523364 nnns volume:4 year:2018 number:2 pages:80-84 https://doi.org/10.1016/j.jons.2018.06.001 kostenfrei https://doaj.org/article/5a820194e0fc47629a982aed4ba5ecb9 kostenfrei http://www.sciencedirect.com/science/article/pii/S245233641830013X kostenfrei https://doaj.org/toc/2452-3364 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2018 2 80-84
spelling	10.1016/j.jons.2018.06.001 doi (DE-627)DOAJ006508707 (DE-599)DOAJ5a820194e0fc47629a982aed4ba5ecb9 DE-627 ger DE-627 rakwb eng RC254-282 Fatma Ceyda Korucu verfasserin aut A retrospective study on potential drug interactions: A single center experience 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: In this study, it is aimed to explain the type and frequency of potential drug-drug interactions (pDDI) in patients a Medical oncology service. Methods: This study retrospective descriptive design. pDDIs were identified using the checker programme (Medscape®). Interactions were classified according to their clinical relevance as minor, moderate and major as appropriate. Results: The prevalence of pDDIs was 71.3% and median age was 61 years-old (interquartile range 54–68) and female to male ratio was 116/211. The median number of drugs per patient was 8 (interquartile range 5–10). A total of 1102 pDDIs of 327 hospitalized cancer patients were identified. Of those, 16.7% were major and 61.8% moderate, respectively. Concomitant use of opioids was the most common interaction in our study. Conclusions: Drug interactions were common in hospitalized cancer patients. In order to prevent potential hazardous effect of pDDI, awareness of the physicians should be increased about this issue. Keywords: Cancer patients, Oncology, Polypharmacy, Drug interaction, Chemotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens Ece Senyigit verfasserin aut Osman Köstek verfasserin aut Nazım Can Demircan verfasserin aut Bulent Erdogan verfasserin aut Sernaz Uzunoglu verfasserin aut Irfan Cicin verfasserin aut In Journal of Oncological Sciences Turkiye Klinikleri, 2017 4(2018), 2, Seite 80-84 (DE-627)860839109 (DE-600)2858461-2 24523364 nnns volume:4 year:2018 number:2 pages:80-84 https://doi.org/10.1016/j.jons.2018.06.001 kostenfrei https://doaj.org/article/5a820194e0fc47629a982aed4ba5ecb9 kostenfrei http://www.sciencedirect.com/science/article/pii/S245233641830013X kostenfrei https://doaj.org/toc/2452-3364 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2018 2 80-84
allfields_unstemmed	10.1016/j.jons.2018.06.001 doi (DE-627)DOAJ006508707 (DE-599)DOAJ5a820194e0fc47629a982aed4ba5ecb9 DE-627 ger DE-627 rakwb eng RC254-282 Fatma Ceyda Korucu verfasserin aut A retrospective study on potential drug interactions: A single center experience 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: In this study, it is aimed to explain the type and frequency of potential drug-drug interactions (pDDI) in patients a Medical oncology service. Methods: This study retrospective descriptive design. pDDIs were identified using the checker programme (Medscape®). Interactions were classified according to their clinical relevance as minor, moderate and major as appropriate. Results: The prevalence of pDDIs was 71.3% and median age was 61 years-old (interquartile range 54–68) and female to male ratio was 116/211. The median number of drugs per patient was 8 (interquartile range 5–10). A total of 1102 pDDIs of 327 hospitalized cancer patients were identified. Of those, 16.7% were major and 61.8% moderate, respectively. Concomitant use of opioids was the most common interaction in our study. Conclusions: Drug interactions were common in hospitalized cancer patients. In order to prevent potential hazardous effect of pDDI, awareness of the physicians should be increased about this issue. Keywords: Cancer patients, Oncology, Polypharmacy, Drug interaction, Chemotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens Ece Senyigit verfasserin aut Osman Köstek verfasserin aut Nazım Can Demircan verfasserin aut Bulent Erdogan verfasserin aut Sernaz Uzunoglu verfasserin aut Irfan Cicin verfasserin aut In Journal of Oncological Sciences Turkiye Klinikleri, 2017 4(2018), 2, Seite 80-84 (DE-627)860839109 (DE-600)2858461-2 24523364 nnns volume:4 year:2018 number:2 pages:80-84 https://doi.org/10.1016/j.jons.2018.06.001 kostenfrei https://doaj.org/article/5a820194e0fc47629a982aed4ba5ecb9 kostenfrei http://www.sciencedirect.com/science/article/pii/S245233641830013X kostenfrei https://doaj.org/toc/2452-3364 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2018 2 80-84
allfieldsGer	10.1016/j.jons.2018.06.001 doi (DE-627)DOAJ006508707 (DE-599)DOAJ5a820194e0fc47629a982aed4ba5ecb9 DE-627 ger DE-627 rakwb eng RC254-282 Fatma Ceyda Korucu verfasserin aut A retrospective study on potential drug interactions: A single center experience 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: In this study, it is aimed to explain the type and frequency of potential drug-drug interactions (pDDI) in patients a Medical oncology service. Methods: This study retrospective descriptive design. pDDIs were identified using the checker programme (Medscape®). Interactions were classified according to their clinical relevance as minor, moderate and major as appropriate. Results: The prevalence of pDDIs was 71.3% and median age was 61 years-old (interquartile range 54–68) and female to male ratio was 116/211. The median number of drugs per patient was 8 (interquartile range 5–10). A total of 1102 pDDIs of 327 hospitalized cancer patients were identified. Of those, 16.7% were major and 61.8% moderate, respectively. Concomitant use of opioids was the most common interaction in our study. Conclusions: Drug interactions were common in hospitalized cancer patients. In order to prevent potential hazardous effect of pDDI, awareness of the physicians should be increased about this issue. Keywords: Cancer patients, Oncology, Polypharmacy, Drug interaction, Chemotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens Ece Senyigit verfasserin aut Osman Köstek verfasserin aut Nazım Can Demircan verfasserin aut Bulent Erdogan verfasserin aut Sernaz Uzunoglu verfasserin aut Irfan Cicin verfasserin aut In Journal of Oncological Sciences Turkiye Klinikleri, 2017 4(2018), 2, Seite 80-84 (DE-627)860839109 (DE-600)2858461-2 24523364 nnns volume:4 year:2018 number:2 pages:80-84 https://doi.org/10.1016/j.jons.2018.06.001 kostenfrei https://doaj.org/article/5a820194e0fc47629a982aed4ba5ecb9 kostenfrei http://www.sciencedirect.com/science/article/pii/S245233641830013X kostenfrei https://doaj.org/toc/2452-3364 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2018 2 80-84
allfieldsSound	10.1016/j.jons.2018.06.001 doi (DE-627)DOAJ006508707 (DE-599)DOAJ5a820194e0fc47629a982aed4ba5ecb9 DE-627 ger DE-627 rakwb eng RC254-282 Fatma Ceyda Korucu verfasserin aut A retrospective study on potential drug interactions: A single center experience 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background: In this study, it is aimed to explain the type and frequency of potential drug-drug interactions (pDDI) in patients a Medical oncology service. Methods: This study retrospective descriptive design. pDDIs were identified using the checker programme (Medscape®). Interactions were classified according to their clinical relevance as minor, moderate and major as appropriate. Results: The prevalence of pDDIs was 71.3% and median age was 61 years-old (interquartile range 54–68) and female to male ratio was 116/211. The median number of drugs per patient was 8 (interquartile range 5–10). A total of 1102 pDDIs of 327 hospitalized cancer patients were identified. Of those, 16.7% were major and 61.8% moderate, respectively. Concomitant use of opioids was the most common interaction in our study. Conclusions: Drug interactions were common in hospitalized cancer patients. In order to prevent potential hazardous effect of pDDI, awareness of the physicians should be increased about this issue. Keywords: Cancer patients, Oncology, Polypharmacy, Drug interaction, Chemotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens Ece Senyigit verfasserin aut Osman Köstek verfasserin aut Nazım Can Demircan verfasserin aut Bulent Erdogan verfasserin aut Sernaz Uzunoglu verfasserin aut Irfan Cicin verfasserin aut In Journal of Oncological Sciences Turkiye Klinikleri, 2017 4(2018), 2, Seite 80-84 (DE-627)860839109 (DE-600)2858461-2 24523364 nnns volume:4 year:2018 number:2 pages:80-84 https://doi.org/10.1016/j.jons.2018.06.001 kostenfrei https://doaj.org/article/5a820194e0fc47629a982aed4ba5ecb9 kostenfrei http://www.sciencedirect.com/science/article/pii/S245233641830013X kostenfrei https://doaj.org/toc/2452-3364 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2018 2 80-84
language	English
source	In Journal of Oncological Sciences 4(2018), 2, Seite 80-84 volume:4 year:2018 number:2 pages:80-84
sourceStr	In Journal of Oncological Sciences 4(2018), 2, Seite 80-84 volume:4 year:2018 number:2 pages:80-84
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Neoplasms. Tumors. Oncology. Including cancer and carcinogens
isfreeaccess_bool	true
container_title	Journal of Oncological Sciences
authorswithroles_txt_mv	Fatma Ceyda Korucu @@aut@@ Ece Senyigit @@aut@@ Osman Köstek @@aut@@ Nazım Can Demircan @@aut@@ Bulent Erdogan @@aut@@ Sernaz Uzunoglu @@aut@@ Irfan Cicin @@aut@@
publishDateDaySort_date	2018-01-01T00:00:00Z
hierarchy_top_id	860839109
id	DOAJ006508707
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ006508707</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230503143331.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2018 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jons.2018.06.001</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ006508707</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ5a820194e0fc47629a982aed4ba5ecb9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Fatma Ceyda Korucu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="2"><subfield code="a">A retrospective study on potential drug interactions: A single center experience</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: In this study, it is aimed to explain the type and frequency of potential drug-drug interactions (pDDI) in patients a Medical oncology service. Methods: This study retrospective descriptive design. pDDIs were identified using the checker programme (Medscape®). Interactions were classified according to their clinical relevance as minor, moderate and major as appropriate. Results: The prevalence of pDDIs was 71.3% and median age was 61 years-old (interquartile range 54–68) and female to male ratio was 116/211. The median number of drugs per patient was 8 (interquartile range 5–10). A total of 1102 pDDIs of 327 hospitalized cancer patients were identified. Of those, 16.7% were major and 61.8% moderate, respectively. Concomitant use of opioids was the most common interaction in our study. Conclusions: Drug interactions were common in hospitalized cancer patients. In order to prevent potential hazardous effect of pDDI, awareness of the physicians should be increased about this issue. Keywords: Cancer patients, Oncology, Polypharmacy, Drug interaction, Chemotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ece Senyigit</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Osman Köstek</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nazım Can Demircan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Bulent Erdogan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sernaz Uzunoglu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Irfan Cicin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Oncological Sciences</subfield><subfield code="d">Turkiye Klinikleri, 2017</subfield><subfield code="g">4(2018), 2, Seite 80-84</subfield><subfield code="w">(DE-627)860839109</subfield><subfield code="w">(DE-600)2858461-2</subfield><subfield code="x">24523364</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:4</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:80-84</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jons.2018.06.001</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/5a820194e0fc47629a982aed4ba5ecb9</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S245233641830013X</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2452-3364</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">4</subfield><subfield code="j">2018</subfield><subfield code="e">2</subfield><subfield code="h">80-84</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Fatma Ceyda Korucu
spellingShingle	Fatma Ceyda Korucu misc RC254-282 misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens A retrospective study on potential drug interactions: A single center experience
authorStr	Fatma Ceyda Korucu
ppnlink_with_tag_str_mv	@@773@@(DE-627)860839109
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC254-282
illustrated	Not Illustrated
issn	24523364
topic_title	RC254-282 A retrospective study on potential drug interactions: A single center experience
topic	misc RC254-282 misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_unstemmed	misc RC254-282 misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_browse	misc RC254-282 misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Journal of Oncological Sciences
hierarchy_parent_id	860839109
hierarchy_top_title	Journal of Oncological Sciences
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)860839109 (DE-600)2858461-2
title	A retrospective study on potential drug interactions: A single center experience
ctrlnum	(DE-627)DOAJ006508707 (DE-599)DOAJ5a820194e0fc47629a982aed4ba5ecb9
title_full	A retrospective study on potential drug interactions: A single center experience
author_sort	Fatma Ceyda Korucu
journal	Journal of Oncological Sciences
journalStr	Journal of Oncological Sciences
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2018
contenttype_str_mv	txt
container_start_page	80
author_browse	Fatma Ceyda Korucu Ece Senyigit Osman Köstek Nazım Can Demircan Bulent Erdogan Sernaz Uzunoglu Irfan Cicin
container_volume	4
class	RC254-282
format_se	Elektronische Aufsätze
author-letter	Fatma Ceyda Korucu
doi_str_mv	10.1016/j.jons.2018.06.001
author2-role	verfasserin
title_sort	retrospective study on potential drug interactions: a single center experience
callnumber	RC254-282
title_auth	A retrospective study on potential drug interactions: A single center experience
abstract	Background: In this study, it is aimed to explain the type and frequency of potential drug-drug interactions (pDDI) in patients a Medical oncology service. Methods: This study retrospective descriptive design. pDDIs were identified using the checker programme (Medscape®). Interactions were classified according to their clinical relevance as minor, moderate and major as appropriate. Results: The prevalence of pDDIs was 71.3% and median age was 61 years-old (interquartile range 54–68) and female to male ratio was 116/211. The median number of drugs per patient was 8 (interquartile range 5–10). A total of 1102 pDDIs of 327 hospitalized cancer patients were identified. Of those, 16.7% were major and 61.8% moderate, respectively. Concomitant use of opioids was the most common interaction in our study. Conclusions: Drug interactions were common in hospitalized cancer patients. In order to prevent potential hazardous effect of pDDI, awareness of the physicians should be increased about this issue. Keywords: Cancer patients, Oncology, Polypharmacy, Drug interaction, Chemotherapy
abstractGer	Background: In this study, it is aimed to explain the type and frequency of potential drug-drug interactions (pDDI) in patients a Medical oncology service. Methods: This study retrospective descriptive design. pDDIs were identified using the checker programme (Medscape®). Interactions were classified according to their clinical relevance as minor, moderate and major as appropriate. Results: The prevalence of pDDIs was 71.3% and median age was 61 years-old (interquartile range 54–68) and female to male ratio was 116/211. The median number of drugs per patient was 8 (interquartile range 5–10). A total of 1102 pDDIs of 327 hospitalized cancer patients were identified. Of those, 16.7% were major and 61.8% moderate, respectively. Concomitant use of opioids was the most common interaction in our study. Conclusions: Drug interactions were common in hospitalized cancer patients. In order to prevent potential hazardous effect of pDDI, awareness of the physicians should be increased about this issue. Keywords: Cancer patients, Oncology, Polypharmacy, Drug interaction, Chemotherapy
abstract_unstemmed	Background: In this study, it is aimed to explain the type and frequency of potential drug-drug interactions (pDDI) in patients a Medical oncology service. Methods: This study retrospective descriptive design. pDDIs were identified using the checker programme (Medscape®). Interactions were classified according to their clinical relevance as minor, moderate and major as appropriate. Results: The prevalence of pDDIs was 71.3% and median age was 61 years-old (interquartile range 54–68) and female to male ratio was 116/211. The median number of drugs per patient was 8 (interquartile range 5–10). A total of 1102 pDDIs of 327 hospitalized cancer patients were identified. Of those, 16.7% were major and 61.8% moderate, respectively. Concomitant use of opioids was the most common interaction in our study. Conclusions: Drug interactions were common in hospitalized cancer patients. In order to prevent potential hazardous effect of pDDI, awareness of the physicians should be increased about this issue. Keywords: Cancer patients, Oncology, Polypharmacy, Drug interaction, Chemotherapy
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	2
title_short	A retrospective study on potential drug interactions: A single center experience
url	https://doi.org/10.1016/j.jons.2018.06.001 https://doaj.org/article/5a820194e0fc47629a982aed4ba5ecb9 http://www.sciencedirect.com/science/article/pii/S245233641830013X https://doaj.org/toc/2452-3364
remote_bool	true
author2	Ece Senyigit Osman Köstek Nazım Can Demircan Bulent Erdogan Sernaz Uzunoglu Irfan Cicin
author2Str	Ece Senyigit Osman Köstek Nazım Can Demircan Bulent Erdogan Sernaz Uzunoglu Irfan Cicin
ppnlink	860839109
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1016/j.jons.2018.06.001
callnumber-a	RC254-282
up_date	2024-07-03T21:20:55.438Z
_version_	1803594398897799168
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ006508707</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230503143331.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2018 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jons.2018.06.001</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ006508707</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ5a820194e0fc47629a982aed4ba5ecb9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Fatma Ceyda Korucu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="2"><subfield code="a">A retrospective study on potential drug interactions: A single center experience</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: In this study, it is aimed to explain the type and frequency of potential drug-drug interactions (pDDI) in patients a Medical oncology service. Methods: This study retrospective descriptive design. pDDIs were identified using the checker programme (Medscape®). Interactions were classified according to their clinical relevance as minor, moderate and major as appropriate. Results: The prevalence of pDDIs was 71.3% and median age was 61 years-old (interquartile range 54–68) and female to male ratio was 116/211. The median number of drugs per patient was 8 (interquartile range 5–10). A total of 1102 pDDIs of 327 hospitalized cancer patients were identified. Of those, 16.7% were major and 61.8% moderate, respectively. Concomitant use of opioids was the most common interaction in our study. Conclusions: Drug interactions were common in hospitalized cancer patients. In order to prevent potential hazardous effect of pDDI, awareness of the physicians should be increased about this issue. Keywords: Cancer patients, Oncology, Polypharmacy, Drug interaction, Chemotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ece Senyigit</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Osman Köstek</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nazım Can Demircan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Bulent Erdogan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sernaz Uzunoglu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Irfan Cicin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Oncological Sciences</subfield><subfield code="d">Turkiye Klinikleri, 2017</subfield><subfield code="g">4(2018), 2, Seite 80-84</subfield><subfield code="w">(DE-627)860839109</subfield><subfield code="w">(DE-600)2858461-2</subfield><subfield code="x">24523364</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:4</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:80-84</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jons.2018.06.001</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/5a820194e0fc47629a982aed4ba5ecb9</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S245233641830013X</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2452-3364</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">4</subfield><subfield code="j">2018</subfield><subfield code="e">2</subfield><subfield code="h">80-84</subfield></datafield></record></collection>
score	7.400179

Nicht das Richtige dabei?

Schreiben Sie uns!

A retrospective study on potential drug interactions: A single center experience

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?